These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26306982)

  • 21. Design, synthesis, and biological evaluation of novel selective peptide inhibitors of 11β-hydroxysteroid dehydrogenase 1.
    Boudon S; Heidl M; Vuorinen A; Wandeler E; Campiche R; Odermatt A; Jackson E
    Bioorg Med Chem; 2018 Oct; 26(18):5128-5139. PubMed ID: 30245006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: potential impact in diabetes.
    Deng X; Shen Y; Yang J; He J; Zhao Y; Peng LY; Leng Y; Zhao QS
    Eur J Med Chem; 2013 Jul; 65():403-14. PubMed ID: 23747808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
    Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.
    Sorensen B; Winn M; Rohde J; Shuai Q; Wang J; Fung S; Monzon K; Chiou W; Stolarik D; Imade H; Pan L; Deng X; Chovan L; Longenecker K; Judge R; Qin W; Brune M; Camp H; Frevert EU; Jacobson P; Link JT
    Bioorg Med Chem Lett; 2007 Jan; 17(2):527-32. PubMed ID: 17070044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
    Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
    Xia G; You X; Liu L; Liu H; Wang J; Shi Y; Li P; Xiong B; Liu X; Shen J
    Eur J Med Chem; 2013 Apr; 62():1-10. PubMed ID: 23353742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
    Patel JR; Shuai Q; Dinges J; Winn M; Pliushchev M; Fung S; Monzon K; Chiou W; Wang J; Pan L; Wagaw S; Engstrom K; Kerdesky FA; Longenecker K; Judge R; Qin W; Imade HM; Stolarik D; Beno DW; Brune M; Chovan LE; Sham HL; Jacobson P; Link JT
    Bioorg Med Chem Lett; 2007 Feb; 17(3):750-5. PubMed ID: 17110106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 11β-hydroxysteroid dehydrogenase type 1 inhibitor.
    Hong SP; Nam KY; Shin YJ; Kim KW; Ahn SK
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3501-6. PubMed ID: 26187704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of SAR184841, a potent and long-lasting inhibitor of 11β-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.
    Venier O; Pascal C; Braun A; Namane C; Mougenot P; Crespin O; Pacquet F; Mougenot C; Monseau C; Onofri B; Dadji-Faïhun R; Leger C; Ben-Hassine M; Van-Pham T; Ragot JL; Philippo C; Farjot G; Noah L; Maniani K; Boutarfa A; Nicolaï E; Guillot E; Pruniaux MP; Güssregen S; Engel C; Coutant AL; de Miguel B; Castro A
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2414-21. PubMed ID: 23478147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
    Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-Amino-N-adamantyl-3-methylbutanamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitor.
    Lee Y; Shin YJ; Ahn SK
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1421-5. PubMed ID: 24507919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction.
    Leiva R; Griñan-Ferré C; Seira C; Valverde E; McBride A; Binnie M; Pérez B; Luque FJ; Pallàs M; Bidon-Chanal A; Webster SP; Vázquez S
    Eur J Med Chem; 2017 Oct; 139():412-428. PubMed ID: 28818766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
    Ye XY; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Li YX; He B; Kirby M; Gordon DA; Robl JA
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6699-704. PubMed ID: 21983439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
    Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
    Ryu JH; Lee JA; Kim S; Shin YA; Yang J; Han HY; Son HJ; Kim YH; Sa JH; Kim JS; Lee J; Lee J; Park HG
    J Med Chem; 2016 Nov; 59(22):10176-10189. PubMed ID: 27798827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
    Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
    J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1.
    Xia G; Liu L; Xue M; Liu H; Yu J; Li P; Chen Q; Xiong B; Liu X; Shen J
    Mol Cell Endocrinol; 2012 Jul; 358(1):46-52. PubMed ID: 22410288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.